FutureChem Co.,Ltd (KOSDAQ:220100)

Market Cap	503.38B +25.7%
Revenue (ttm)	18.75B +19.2%
Net Income	-4.24B
EPS	-191.73
Shares Out	22.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	253,277
Average Volume	287,516
Open	22,750
Previous Close	23,700
Day's Range	21,750 - 23,150
52-Week Range	14,900 - 35,050
Beta	0.71
RSI	33.36
Earnings Date	Nov 13, 2025

About FutureChem Co.,Ltd

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of prostate cancer; F-FMT for brain tumor diagnosis; FC-505 for the treatment ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 220100

Financial Performance

In 2024, FutureChem Co.,Ltd's revenue was 17.29 billion, an increase of 23.81% compared to the previous year's 13.97 billion. Losses were -9.42 billion, 40.4% more than in 2023.